ATC code G04
ATC code G04 Urologicals is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3] Subgroup G04 is part of the anatomical group G Genito-urinary system and sex hormones.[4]
| ATC code G: Genito-urinary system and sex hormones |
|---|
|
| ATCvet only |
|
| Other ATC codes |
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QG04.[5] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
G04B Urologicals
G04BA Acidifiers
- G04BA01 Ammonium chloride
- G04BA03 Calcium chloride
- QG04BA90 Methionine
G04BC Urinary concrement solvents
- Empty group
G04BD Drugs for urinary frequency and incontinence
- G04BD01 Emepronium
- G04BD02 Flavoxate
- G04BD03 Meladrazine
- G04BD04 Oxybutynin
- G04BD05 Terodiline
- G04BD06 Propiverine
- G04BD07 Tolterodine
- G04BD08 Solifenacin
- G04BD09 Trospium
- G04BD10 Darifenacin
- G04BD11 Fesoterodine
- G04BD12 Mirabegron
- G04BD13 Desfesoterodine
- G04BD14 Imidafenacin
G04BE Drugs used in erectile dysfunction
- G04BE01 Alprostadil
- G04BE02 Papaverine
- G04BE03 Sildenafil
- G04BE04 Yohimbin
- G04BE05 Phentolamine
- G04BE06 Moxisylyte
- G04BE07 Apomorphine
- G04BE08 Tadalafil
- G04BE09 Vardenafil
- G04BE10 Avanafil
- G04BE11 Udenafil
- G04BE30 Combinations
- G04BE52 Papaverine, combinations
QG04BQ Urinary alkalizers
- QG04BQ01 Sodium bicarbonate
G04BX Other urologicals
- G04BX01 Magnesium hydroxide
- G04BX03 Acetohydroxamic acid
- G04BX06 Phenazopyridine
- G04BX10 Succinimide
- G04BX11 Collagen
- G04BX12 Phenyl salicylate
- G04BX13 Dimethyl sulfoxide
- G04BX14 Dapoxetine
- G04BX15 Pentosan polysulfate sodium
- G04BX16 Tiopronin
- QG04BX56 Phenazopyridine, combinations
- QG04BX90 Ephedrine
- QG04BX91 Phenylpropanolamine
G04C Drugs used in benign prostatic hypertrophy
G04CA Alpha-adrenoreceptor antagonists
- G04CA01 Alfuzosin
- G04CA02 Tamsulosin
- G04CA03 Terazosin
- G04CA04 Silodosin
- G04CA51 Alfuzosin and finasteride
- G04CA52 Tamsulosin and dutasteride
- G04CA53 Tamsulosin and solifenacin
- G04CA54 Tamsulosin and tadalafil
- G04CA55 Doxazosin and finasteride
G04CB Testosterone-5-alpha reductase inhibitors
- G04CB01 Finasteride
- G04CB02 Dutasteride
- G04CB51 Finasteride and tadalafil
G04CX Other drugs used in benign prostatic hypertrophy
- G04CX01 Prunus africanae cortex
- G04CX02 Sabalis serrulatae fructus
- G04CX03 Mepartricin
- G04CX04 Fexapotide
- QG04CX90 Osaterone
References
- "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- "ATC/DDD Index 2022: code G04". WHO Collaborating Centre for Drug Statistics Methodology.
- "ATCvet Index 2022: code QG04". WHO Collaborating Centre for Drug Statistics Methodology.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.